Zai Lab Limited Stock Price, News & Analysis

Zai Lab Limited (NASDAQ: ZLAB) announced the dosing of the first patient in the Greater China segment of the global ADHERE study for efgartigimod, targeting chronic inflammatory demyelinating polyneuropathy (CIDP). The trial, consisting of an open-label Stage A and a randomized Stage B, will assess the safety and efficacy of weekly subcutaneous efgartigimod over 48 weeks. CIDP affects around 50,000 patients in China, with limited treatment options available. The potential of efgartigimod is notable due to the need for effective alternatives to corticosteroids and IVIg therapy.

Zai Lab Limited (NASDAQ: ZLAB) announced that the first patient has been treated in China's Phase 3 ADDRESS study of efgartigimod for pemphigus vulgaris (PV) and pemphigus foliaceus (PF). This randomized, double-blind trial aims to evaluate the drug’s safety and efficacy in roughly 150 patients. Efgartigimod targets IgG antibodies, offering potential for better disease management in these severe autoimmune disorders. Pemphigus affects approximately 90,000 patients in China, highlighting a significant unmet need for effective treatments.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced the treatment of the first patient with primary immune thrombocytopenia (ITP) using efgartigimod in Greater China as part of the global ADVANCE-SC Phase 3 study. This randomized trial aims to assess the efficacy and safety of efgartigimod, which has previously shown promising results in improving platelet counts in ITP patients. The study highlights the urgent need for new therapies for the 120,000 ITP patients in Greater China who currently face limited treatment options.

Zai Lab Limited (NASDAQ: ZLAB) reported strong third-quarter 2021 results, with net product revenues of $43.1 million, up from $14.7 million year-over-year. Key highlights include the expansion of its product pipeline with three new potential first-in-class medicines and solid growth in marketed products: ZEJULA, OPTUNE, and QINLOCK. Despite a net loss of $96.4 million, up from $63.7 million in Q3 2020, the company's cash reserves increased to $1.57 billion. Anticipated milestones include upcoming clinical trial results and regulatory submissions, indicating a robust future outlook.

Zai Lab has secured exclusive rights to develop and commercialize the next-generation EGFR inhibitors, BLU-945 and BLU-701, in Greater China. This partnership with Blueprint Medicines includes a $25 million upfront payment and potential milestone payments of up to $590 million, alongside tiered royalties. The collaboration aims to address significant medical needs in treating non-small cell lung cancer (NSCLC) with EGFR mutations, which affect 40-50% of patients in the region. Zai Lab is responsible for development costs in this territory.

Blueprint Medicines and Zai Lab have entered into an exclusive collaboration to develop BLU-945 and BLU-701 for EGFR-driven non-small cell lung cancer (NSCLC) in Greater China. This partnership aims to leverage Blueprint's innovation in precision therapies and Zai Lab's oncology expertise to address the significant medical needs in the region, where a high percentage of NSCLC patients have EGFR mutations. Blueprint will receive an upfront payment of $25 million and potential milestones totaling $590 million, with Zai Lab managing development costs.

Zai Lab has secured exclusive rights to develop and commercialize KarXT (xanomeline-trospium) in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. The agreement entails an upfront payment of $35 million to Karuna Therapeutics and potential milestone payments up to $152 million. Zai Lab will undertake the development and commercialization efforts, with tiered royalties on net sales. KarXT targets psychiatric conditions, showing promising results in late-stage trials for schizophrenia and Alzheimer's-related psychosis.

Zai Lab has secured exclusive rights to develop and commercialize KarXT in Greater China through a new collaboration with Karuna Therapeutics. The agreement includes a $35 million upfront payment and potential milestones totaling up to $152 million, along with royalties based on sales. KarXT is an investigational treatment for psychiatric conditions, showing significant efficacy in clinical trials. The partnership aims to address the substantial need for effective therapies in schizophrenia and dementia-related psychosis in the region.

Zai Lab has secured exclusive rights to develop and commercialize KarXT in Greater China, with a total deal value exceeding $267 million. Karuna Therapeutics will receive an upfront payment of $35 million along with potential milestone payments of up to $152 million and tiered royalties. KarXT has shown promising results in treating schizophrenia and Alzheimer’s-related psychosis, with ongoing late-stage trials. Zai Lab will oversee development and commercialization efforts in the region.